Eur J Pharmacol . 2020 Jun 5;876:173049. doi: 10.1016/j.ejphar.2020.173049. Epub 2020 Mar 3.

Systemic and Local Delivery of Mesenchymal Stem Cells for Heart Renovation: Challenges and Innovations

Ziwei Liu  ¹ , Reyaj Mikrani  ¹ , Hafiz Muhammad Zubair  ² , Abdoh Taleb  ³ , Muhammad Naveed  ³ , Mirza Muhammad Faran Asraf Baig  ⁴ , Qin Zhang  ¹ , Cuican Li  ¹ , Murad Habib  ⁵ , Xingxing Cui  ¹ , Kiganda Raymond Sembatya  ¹ , Han Lei  ⁶ , Xiaohui Zhou  ⁷

Abstract

In the beginning stage of heart disease, the blockage of blood flow frequently occurs due to the persistent damage and even death of myocardium. Cicatricial tissue developed after the death of myocardium can affect heart function, which ultimately leads to heart failure. In recent years, several studies carried out about the use of stem cells such as embryonic, pluripotent, cardiac and bone marrow-derived stem cells as well as myoblasts to repair injured myocardium. Current studies focus more on finding appropriate measures to enhance cell homing and survival in order to increase paracrine function. Until now, there is no universal delivery route for mesenchymal stem cells (MSCs) for different diseases. In this review, we summarize the advantages and challenges of the systemic and local pathways of MSC delivery. In addition, we also describe some advanced measures of cell delivery to improve the efficiency of transplantation. The combination of cells and therapeutic substances could be the most reliable method, which allows donor cells to deliver sufficient amounts of paracrine factors and provide long-lasting effects. The cardiac support devices or tissue engineering techniques have the potential to facilitate the controlled release of stem cells on local tissue for a sustained period. A novel promising epicardial drug delivery system is highlighted here, which not only provides MSCs with a favorable environment to promote retention but also increases the contact area and a number of cells recruited in the heart muscle.